A solid matrix sustained release ophthalmic formulation for topical delivery of a solid ophthalmic drug to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period provided herein. The formulation disclosed herein is an admixture of an ophthalmic drug, and a combination of a hydrophobic polymer, a hydrophilic polymer and a surfactant, wherein the drug is eluted daily over an extended period of time at therapeutic dose of drug.

A light adjustable lens illumination system comprises an illumination source, for generating a light beam; a light delivery system, for projecting the light beam onto a Light Adjustable Lens (LAL), implanted into an eye, wherein a fraction of the light beam propagates past the LAL to a retina of the eye; and a protective beam-shaper, for shaping the light beam to have an intensity pattern with a relative central intensity reduction that varies along an axis; wherein the relative central intensity reduction at the retina is greater than the relative central intensity reduction at a LAL plane.

This invention relates to novel implant drug delivery systems for long-acting delivery of mometasone furoate. These compositions are useful for the treatment or prevention of inflammatory conditions of the eye.

The present disclosure describes a method for treating or preventing an inflammatory ocular surface disease or disorder, such as ocular graft-versus-host disease, dry eye, meibomian gland disease, thyroid eye disease, blepharitis, Sjogren's syndrome, peripheral ulcerative keratitis, or Stevens-Johnson syndrome, in a human subject in need thereof, the method comprising (a) administering a topical progesterone composition to the forehead of the subject; (b) administering punctal plugs to the subject; and (c) administering a opical corticosteroid composition, such as loteprednol etabonate ointment, to the eye of the subject. Such administration methods may also be useful in improving corneal health before cataract surgery and/or promoting healing of the cornea after cataract surgery.

The present technology relates to adjustable shunting systems and methods. In some embodiments, the present technology includes an adjustable shunting system that includes a drainage element having an inflow portion configured for placement within a patient. The system can also include a flow control assembly having a gating element operably coupled to the outflow portion of the drainage element. The flow control assembly can further include a first actuation element and a second actuation element coupled to the gating element. The first and second actuation elements can be configured to selectively move the gating element relative to the outflow portion to control an amount of fluid flow therethrough. The first and second actuation elements can each extend less than entirely around a perimeter of the drainage element.

A method and device for reducing intraocular pressure in a patient. The method may comprise administering a viscoelastic material in Schlemm's canal to open aqueous humor outflow pathways. The device is adapted to perform the method. The viscoelastic material may be configured to lower the intraocular pressure within the eye.

Injection devices for delivering pharmaceutical compositions into the eye are described. Some devices include a resistance component for controllably deploying an injection needle through the eye wall. The resistance component may be disposed on the injector device, or on a portion of the injection device housing, or on a drug reservoir. Some devices may be removably attached to a drug reservoir, for example, through a luer connector. Other devices may comprise internal luer seal for securely connecting a drug conduit of the device to the luer cavity of a drug reservoir. Yet other devices may comprise a priming-enabling element to facilitate the drug priming of a shielded needle. Related methods and systems comprising the devices are also described.

An artificial eye assembly (100) comprising: ⋅an anterior layer (50) comprising an anterior cavity (52); ⋅a flow con-stricting (40) layer comprising a first aperture (42), and wherein the first aperture (42) is in fluid communication with the anterior cavity (52); ⋅a shaping layer (30) comprising a second aperture and a shaping structure (32), wherein the shaping structure (32) is located within, partially within, or outside of the second aperture, and wherein the shaping structure comprises (32) one or more webs (33), the webs (33) connecting the structure (32) to the rest of the shaping layer (30), and wherein the second aperture is in fluid communication with the first aperture (42); ⋅a flow resistive layer (20) comprising pores, and wherein pores of the layer are in fluid communication with the second aperture; ⋅a posterior layer (10) comprising a posterior cavity (12), and wherein the posterior cavity (12) is in fluid communication with pores of the flow resistive layer (20); ⋅a fluid inlet (13) located in the anterior and/or posterior cavity (12, 52), or located in or adjacent to the second aperture; ⋅a fluid outlet (54) located in the anterior cavity; ⋅and an injection inlet (14) located in the posterior cavity and/or located in the anterior cavity, and wherein the anterior cavity (52) and the posterior cavity (12) are in fluid communication with one another via a fluid path formed through the layers (10, 20, 30, 40 50); and wherein, in use, a fluid introduced under pressure into the assembly via the fluid inlet (13) will flow along the fluid path and exit the assembly via the fluid outlet (54) with a first flow rate.

A surgical instrument, and methods for its use, is described that includes clamp heads that can be nestled within or extended from a tubular sheath by longitudinal movement of the clamp heads' tines with respect to the tubular sheath. One of the tines includes an arch that slides against a mouth and inside wall of the tubular sheath, causing the clamp heads to open or close. The clamp heads close lightly, to within a predetermined (or zero) distance from one another, gently grasp an ultrathin polymer substrate seeded with cells, and pulls it within the sheath such that the substrate curls and folds to protect the cells.

Methods and systems for applying beta radiation and an anti-VEGF compound to a treatment area, such as a target area of a bleb, before, during, or after glaucoma surgery. The methods and systems herein may help reduce intraocular pressure, achieve and/or maintain a healthy intraocular pressure, maintain functioning blebs and/or drainage holes arising from glaucoma drainage procedures or surgeries, help avoid scar formation or wound reversion, inhibit or reduce fibrogenesis and/or inflammation in the blebs or surrounding areas, etc.